Ignite Creation Date:
2024-05-06 @ 7:54 PM
Last Modification Date:
2024-10-26 @ 3:16 PM
Study NCT ID:
NCT06172660
Status:
RECRUITING
Last Update Posted:
2024-04-24
First Post:
2023-12-06
Brief Title:
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to continue evaluating how well the RSV vaccines work as they are currently being used in routine clinical practice Some of the questions that the investigators hope to answer with this study are 1 What is the overall effectiveness of these vaccines 2 How long does immunity last 3 How effective are the vaccines against new strains 3 Does the vaccines effectiveness vary by age
Detailed Description:
This will be a large-scale case-control study aiming to evaluate the effectiveness of perinatal RSV immunoprophylaxis Cases and controls will be identified using active surveillance in both inpatient and outpatient clinical sites of the Yale New Haven Health System Investigators will enroll patients seeking health care for acute respiratory illness and confirm RSV infection using approved molecular assays Data will be collected from multiple sources including health records interviews immunization registries and population-based surveys Investigators will generate estimates of effectiveness for each type of immunization used disaggregated by time from immunization disease severity and sociodemographic characteristics Aim 1 Investigators will also perform genetic characterization of all RSV viruses in the study monitor the genetic diversity of the virus over time and quantify the relative effectiveness of immunoprophylaxis against various viral lineages Aim 2 Finally investigators will collect acute and convalescent blood from a subset of infants and employ a single-cell and multi-omics approach to study the dynamics of the innate and adaptive immune responses during RSV infection and explore the molecular mechanisms that contribute to immunoprophylaxis failure Aim 3
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01AI179874-01 | NIH | None | httpsreporternihgovquickSearch1R01AI179874-01 |